Related Experiment Videos
Responsiveness to three bronchial provocation tests in patients with asthma
Heikki O Koskela1, Liisa Hyvärinen, John D Brannan
1Department of Respiratory Medicine, Kuopio University Hospital, PL 1777, 70210 Kuopio, Finland. heikki.koskela@kuh.fi
Chest
|December 11, 2003
Summary
The mannitol challenge is more sensitive than cold air for diagnosing airway hyperresponsiveness in mild or atypical asthma. Mannitol and histamine challenges show comparable sensitivity when using a specific histamine provocative dose cut-off.
Area of Science:
- Pulmonology
- Respiratory Medicine
- Diagnostic Testing
Background:
- Diagnosing mild or atypical asthma can be challenging.
- Airway hyperresponsiveness (AHR) is a key feature of asthma.
- Novel diagnostic tools are needed for difficult-to-diagnose asthma cases.
Purpose of the Study:
- To compare the sensitivity of a new mannitol bronchial provocation test against cold air and histamine challenges.
- To evaluate the effectiveness of these tests in demonstrating AHR in patients with difficult-to-diagnose asthma.
Main Methods:
- A prospective study involving 37 recently diagnosed, steroid-naive asthma patients and 10 healthy controls.
- Participants underwent spirometry, diffusion capacity measurement, skin-prick tests, and bronchial provocation tests (mannitol, cold air, histamine).
- Asthma severity was classified using the Global Initiative for Asthma (GINA) guidelines.
Main Results:
- Mannitol demonstrated AHR in 51% of asthma patients, cold air in 24%, and histamine in 81% (PD(15) < 1.0 mg) or 49% (PD(15) < 0.4 mg).
- No healthy controls responded to any challenge.
- GINA classification did not correlate with responsiveness to the provocation tests.
Conclusions:
- Mannitol is more sensitive than cold air for detecting AHR in mild or atypical asthma.
- Histamine challenge sensitivity is comparable to mannitol when using a PD(15) cut-off of 0.4 mg, considered specific for asthma diagnosis.
- The mannitol challenge offers a valuable alternative for diagnosing AHR in specific asthma populations.